INTERESTED IN GETTING YOUR HANDS ON MONOCLONAL ANTIBODIES?

Click the image for more details

 

INNOVATORS  

"Onco Med Pharmaceutical is a clinical stage company that discovers and develops novel therapeutics targeting cancer stem cells. The cells believed to be capable of driving tumor growth and more. A leader in cancer stem cell research, the company has establish a library of antibodies to cancer stem cell proteins for the treatment of solid tumors such a pancreatic, breast, colorectal and lung cancers. Currently, they are waiting Phase 1 of clinical trials." 

"Campath is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia. About 95% of CLL cases involve cancerous B cells that happen to crowd out the healthy cells, causing infection and/or symptoms. Campath targets these diseased blood cells for destruction."

"Herceptin is a biologically engineered, monoclonal antibody designed to target and block the function of Human Epidermal growth factor Receptor 2. It is the first MAb-based therapy used to treat breast cancer, the second most common cancer in the world." 

"Rituxan help the B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to Rituxan in combination with chemotherapy, as a single-agent maintenance therapy. This products help to fight agaisnt Non-Hodgkin's lymphoma which is a cancer that develops in the lymphatic system and Chronic Lymphoma disease."

"Celltrion is a leading biopharmaceutical company in Korea specializing in monoclonal antibody capabilities that contribute to human life. It was established in 2002 with a goal to be the world's leading biopharmaceutical company in the Asian region. Celltrion has built a world-class facility, developed state-of-the-art technologies and established quality systems through active recruitment and investment in a short period of time."

"BioArctic develops monoclonal antibodies for treatment of neurodegenerative diseases. The company's front-runner antibody BAN2401 was developed for treatment of Alzheimer┬┤s disease with clinical trials on-going. Our technology is also applied to other CNS disorders such as Parkinson's disease. The antibodies developed have the unique property to reduce the toxic protofibrils, aggregated/misfolded proteins in the brain."  

"LeukoSite is a biopharmaceutical company located in Cambridge, MA. The company was founded in 1993 with the mission to become a sustainable multi-product pharmaceutical company focused on the discovery, development and commercialization of therapeutics for diseases of the immune system."

Learn more about the many other monoclonal antibody innovators.

Click the image to view the video.  

 

This free website was made using Yola.

No HTML skills required. Build your website in minutes.

Go to www.yola.com and sign up today!

Make a free website with Yola